Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: A study by the Southern Italy Oncology Group (GOIM)

Vittorio Gebbia, Domenico Galetta, Evaristo Majello, Roberto Valenza, Giuseppe Colucci, Nicolò Gebbia

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34% (95% CL 18-54%). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were seen only in 14% and 9% of cases, respectively. Only one patient suffered grade 4 leukopenia. Gastrointestinal toxicity was minimal; only five patients (14%) complained of grade 3 vomiting. This combination regimen can be safely given on an outpatient regimen, but it is relatively active in advanced non-small-cell lung cancer. However, it should be noted that >50% of the patients in this series had a performance status of 50% were older than 65 years.

Original languageEnglish
Pages (from-to)278-280
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number3
DOIs
Publication statusPublished - Jun 1996

Fingerprint

Ifosfamide
Non-Small Cell Lung Carcinoma
Italy
Leukopenia
Therapeutics
vinorelbine
Vomiting
Outpatients
Survival

Keywords

  • Chemotherapy
  • Ifosfamide
  • Metastasis
  • Non-small-cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA : A study by the Southern Italy Oncology Group (GOIM). / Gebbia, Vittorio; Galetta, Domenico; Majello, Evaristo; Valenza, Roberto; Colucci, Giuseppe; Gebbia, Nicolò.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 19, No. 3, 06.1996, p. 278-280.

Research output: Contribution to journalArticle

@article{854b91d5e4ec43188d5efcd8916145b8,
title = "Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: A study by the Southern Italy Oncology Group (GOIM)",
abstract = "Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34{\%} (95{\%} CL 18-54{\%}). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were seen only in 14{\%} and 9{\%} of cases, respectively. Only one patient suffered grade 4 leukopenia. Gastrointestinal toxicity was minimal; only five patients (14{\%}) complained of grade 3 vomiting. This combination regimen can be safely given on an outpatient regimen, but it is relatively active in advanced non-small-cell lung cancer. However, it should be noted that >50{\%} of the patients in this series had a performance status of 50{\%} were older than 65 years.",
keywords = "Chemotherapy, Ifosfamide, Metastasis, Non-small-cell lung cancer, Vinorelbine",
author = "Vittorio Gebbia and Domenico Galetta and Evaristo Majello and Roberto Valenza and Giuseppe Colucci and Nicol{\`o} Gebbia",
year = "1996",
month = "6",
doi = "10.1097/00000421-199606000-00014",
language = "English",
volume = "19",
pages = "278--280",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA

T2 - A study by the Southern Italy Oncology Group (GOIM)

AU - Gebbia, Vittorio

AU - Galetta, Domenico

AU - Majello, Evaristo

AU - Valenza, Roberto

AU - Colucci, Giuseppe

AU - Gebbia, Nicolò

PY - 1996/6

Y1 - 1996/6

N2 - Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34% (95% CL 18-54%). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were seen only in 14% and 9% of cases, respectively. Only one patient suffered grade 4 leukopenia. Gastrointestinal toxicity was minimal; only five patients (14%) complained of grade 3 vomiting. This combination regimen can be safely given on an outpatient regimen, but it is relatively active in advanced non-small-cell lung cancer. However, it should be noted that >50% of the patients in this series had a performance status of 50% were older than 65 years.

AB - Thirty-five patients affected by stage III-IV non-small-cell lung carcinomas were treated with ifosfamide 3 gr/m2 plus MESNA as uroprotector on day 1 and vinorelbine 25 mg/m2 i.v. bolus on day 1 and 8. This cycle was repeated every 21 days. Over a total of 35 evaluable patients, the overall response rate was 34% (95% CL 18-54%). One patient experienced a complete response with a duration of 7.2+ months, and 11 patients a partial response with a mean duration of 5.9+ months. Seven patients had no change and 16 improved. The overall survival was 7.6+ months. Over a total of 145 cycles, the most frequent toxicity was myelosuppression, but grade 3 leukopenia and grade 2 thrombocytopenia were seen only in 14% and 9% of cases, respectively. Only one patient suffered grade 4 leukopenia. Gastrointestinal toxicity was minimal; only five patients (14%) complained of grade 3 vomiting. This combination regimen can be safely given on an outpatient regimen, but it is relatively active in advanced non-small-cell lung cancer. However, it should be noted that >50% of the patients in this series had a performance status of 50% were older than 65 years.

KW - Chemotherapy

KW - Ifosfamide

KW - Metastasis

KW - Non-small-cell lung cancer

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0029975665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029975665&partnerID=8YFLogxK

U2 - 10.1097/00000421-199606000-00014

DO - 10.1097/00000421-199606000-00014

M3 - Article

C2 - 8638541

AN - SCOPUS:0029975665

VL - 19

SP - 278

EP - 280

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -